Adherence to varenicline in the COMPASS smoking cessation intervention trial

Sheryl L Catz, Lisa M. Jack, Jennifer B. McClure, Harold S. Javitz, Mona Deprey, Susan M. Zbikowski, Tim McAfee, Julie Richards, Gary E. Swan

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Introduction: Patient adherence to smoking cessation medications can impact their effectiveness. It is important to understand the extent to which prescribed medications are actually taken by smokers, how this influences smoking cessation outcomes, and what factors may influence adherence. Methods: Smokers recruited from a large health plan were randomized to receive different modes of cessation counseling in combination with varenicline (Swan, G. E., McClure, J. B., Jack, L. M., Zbikowski, S. M., Javitz, H. S., Catz, S. L., et al. 2010. Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine, 38, 482-490). One thousand one hundred and sixty-one participants were mailed a 28-day varenicline supply when they set a quit date and were able to request up to two refills from the health plan pharmacy at no cost. Pharmacy fill records were obtained and telephone surveys completed at baseline, 21 days, 12 weeks, and 6 months post target quit date. Results: Good adherence to varenicline (≥80% of days taken) was associated with a twofold increase in 6-month quit rates compared with poor adherence (52% vs. 25%). Smokers were more likely than nonsmokers to stop varenicline early. Purposeful nonadherence was associated with smoking at 12 weeks and was predicted in multivariate analyses by age, gender, adherence self-efficacy, and initial medication side effect severity. Conclusions: Innovative methods for increasing adherence to smoking cessation medications are needed, particularly early in the quit process. Simple metrics of adherence such as number of days cessation medication is taken can and should be routinely incorporated in effectiveness trials and reported to advance future attempts to understand and reduce nonadherence.

Original languageEnglish (US)
Pages (from-to)361-368
Number of pages8
JournalNicotine and Tobacco Research
Volume13
Issue number5
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Smoking Cessation
Counseling
Preventive Medicine
Health
Self Efficacy
Patient Compliance
Telephone
Multivariate Analysis
Smoking
Varenicline
Costs and Cost Analysis

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Catz, S. L., Jack, L. M., McClure, J. B., Javitz, H. S., Deprey, M., Zbikowski, S. M., ... Swan, G. E. (2011). Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine and Tobacco Research, 13(5), 361-368. https://doi.org/10.1093/ntr/ntr003

Adherence to varenicline in the COMPASS smoking cessation intervention trial. / Catz, Sheryl L; Jack, Lisa M.; McClure, Jennifer B.; Javitz, Harold S.; Deprey, Mona; Zbikowski, Susan M.; McAfee, Tim; Richards, Julie; Swan, Gary E.

In: Nicotine and Tobacco Research, Vol. 13, No. 5, 2011, p. 361-368.

Research output: Contribution to journalArticle

Catz, SL, Jack, LM, McClure, JB, Javitz, HS, Deprey, M, Zbikowski, SM, McAfee, T, Richards, J & Swan, GE 2011, 'Adherence to varenicline in the COMPASS smoking cessation intervention trial', Nicotine and Tobacco Research, vol. 13, no. 5, pp. 361-368. https://doi.org/10.1093/ntr/ntr003
Catz, Sheryl L ; Jack, Lisa M. ; McClure, Jennifer B. ; Javitz, Harold S. ; Deprey, Mona ; Zbikowski, Susan M. ; McAfee, Tim ; Richards, Julie ; Swan, Gary E. / Adherence to varenicline in the COMPASS smoking cessation intervention trial. In: Nicotine and Tobacco Research. 2011 ; Vol. 13, No. 5. pp. 361-368.
@article{a2dbfde96a974b74899cb8445ea491dc,
title = "Adherence to varenicline in the COMPASS smoking cessation intervention trial",
abstract = "Introduction: Patient adherence to smoking cessation medications can impact their effectiveness. It is important to understand the extent to which prescribed medications are actually taken by smokers, how this influences smoking cessation outcomes, and what factors may influence adherence. Methods: Smokers recruited from a large health plan were randomized to receive different modes of cessation counseling in combination with varenicline (Swan, G. E., McClure, J. B., Jack, L. M., Zbikowski, S. M., Javitz, H. S., Catz, S. L., et al. 2010. Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine, 38, 482-490). One thousand one hundred and sixty-one participants were mailed a 28-day varenicline supply when they set a quit date and were able to request up to two refills from the health plan pharmacy at no cost. Pharmacy fill records were obtained and telephone surveys completed at baseline, 21 days, 12 weeks, and 6 months post target quit date. Results: Good adherence to varenicline (≥80{\%} of days taken) was associated with a twofold increase in 6-month quit rates compared with poor adherence (52{\%} vs. 25{\%}). Smokers were more likely than nonsmokers to stop varenicline early. Purposeful nonadherence was associated with smoking at 12 weeks and was predicted in multivariate analyses by age, gender, adherence self-efficacy, and initial medication side effect severity. Conclusions: Innovative methods for increasing adherence to smoking cessation medications are needed, particularly early in the quit process. Simple metrics of adherence such as number of days cessation medication is taken can and should be routinely incorporated in effectiveness trials and reported to advance future attempts to understand and reduce nonadherence.",
author = "Catz, {Sheryl L} and Jack, {Lisa M.} and McClure, {Jennifer B.} and Javitz, {Harold S.} and Mona Deprey and Zbikowski, {Susan M.} and Tim McAfee and Julie Richards and Swan, {Gary E.}",
year = "2011",
doi = "10.1093/ntr/ntr003",
language = "English (US)",
volume = "13",
pages = "361--368",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Adherence to varenicline in the COMPASS smoking cessation intervention trial

AU - Catz, Sheryl L

AU - Jack, Lisa M.

AU - McClure, Jennifer B.

AU - Javitz, Harold S.

AU - Deprey, Mona

AU - Zbikowski, Susan M.

AU - McAfee, Tim

AU - Richards, Julie

AU - Swan, Gary E.

PY - 2011

Y1 - 2011

N2 - Introduction: Patient adherence to smoking cessation medications can impact their effectiveness. It is important to understand the extent to which prescribed medications are actually taken by smokers, how this influences smoking cessation outcomes, and what factors may influence adherence. Methods: Smokers recruited from a large health plan were randomized to receive different modes of cessation counseling in combination with varenicline (Swan, G. E., McClure, J. B., Jack, L. M., Zbikowski, S. M., Javitz, H. S., Catz, S. L., et al. 2010. Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine, 38, 482-490). One thousand one hundred and sixty-one participants were mailed a 28-day varenicline supply when they set a quit date and were able to request up to two refills from the health plan pharmacy at no cost. Pharmacy fill records were obtained and telephone surveys completed at baseline, 21 days, 12 weeks, and 6 months post target quit date. Results: Good adherence to varenicline (≥80% of days taken) was associated with a twofold increase in 6-month quit rates compared with poor adherence (52% vs. 25%). Smokers were more likely than nonsmokers to stop varenicline early. Purposeful nonadherence was associated with smoking at 12 weeks and was predicted in multivariate analyses by age, gender, adherence self-efficacy, and initial medication side effect severity. Conclusions: Innovative methods for increasing adherence to smoking cessation medications are needed, particularly early in the quit process. Simple metrics of adherence such as number of days cessation medication is taken can and should be routinely incorporated in effectiveness trials and reported to advance future attempts to understand and reduce nonadherence.

AB - Introduction: Patient adherence to smoking cessation medications can impact their effectiveness. It is important to understand the extent to which prescribed medications are actually taken by smokers, how this influences smoking cessation outcomes, and what factors may influence adherence. Methods: Smokers recruited from a large health plan were randomized to receive different modes of cessation counseling in combination with varenicline (Swan, G. E., McClure, J. B., Jack, L. M., Zbikowski, S. M., Javitz, H. S., Catz, S. L., et al. 2010. Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine, 38, 482-490). One thousand one hundred and sixty-one participants were mailed a 28-day varenicline supply when they set a quit date and were able to request up to two refills from the health plan pharmacy at no cost. Pharmacy fill records were obtained and telephone surveys completed at baseline, 21 days, 12 weeks, and 6 months post target quit date. Results: Good adherence to varenicline (≥80% of days taken) was associated with a twofold increase in 6-month quit rates compared with poor adherence (52% vs. 25%). Smokers were more likely than nonsmokers to stop varenicline early. Purposeful nonadherence was associated with smoking at 12 weeks and was predicted in multivariate analyses by age, gender, adherence self-efficacy, and initial medication side effect severity. Conclusions: Innovative methods for increasing adherence to smoking cessation medications are needed, particularly early in the quit process. Simple metrics of adherence such as number of days cessation medication is taken can and should be routinely incorporated in effectiveness trials and reported to advance future attempts to understand and reduce nonadherence.

UR - http://www.scopus.com/inward/record.url?scp=79956095931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956095931&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntr003

DO - 10.1093/ntr/ntr003

M3 - Article

C2 - 21350041

AN - SCOPUS:79956095931

VL - 13

SP - 361

EP - 368

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 5

ER -